Duncker Streett & Co. Inc. Has $10.50 Million Stake in Danaher Corporation (NYSE:DHR)

Duncker Streett & Co. Inc. reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,223 shares of the conglomerate's stock after selling 1,278 shares during the period. Danaher comprises approximately 2.1% of Duncker Streett & Co. Inc.'s holdings, making the stock its 13th largest holding. Duncker Streett & Co. Inc.'s holdings in Danaher were worth $10,501,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Danaher during the 4th quarter worth $2,130,740,000. GAMMA Investing LLC boosted its holdings in shares of Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after acquiring an additional 1,863,381 shares during the period. Raymond James Financial Inc. bought a new position in shares of Danaher during the fourth quarter worth about $391,172,000. Two Sigma Advisers LP increased its holdings in shares of Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares during the period. Finally, Capital World Investors lifted its position in Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. TD Cowen upped their target price on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Royal Bank Of Canada reiterated an "outperform" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Wall Street Zen downgraded shares of Danaher from a "buy" rating to a "hold" rating in a research report on Monday, June 9th. Leerink Partners raised their price objective on shares of Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Finally, Wolfe Research cut their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research report on Monday, April 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $248.61.

Insiders Place Their Bets

In other news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.20% of the company's stock.

Danaher Stock Up 0.6%

NYSE:DHR traded up $1.17 during trading hours on Tuesday, hitting $197.51. 2,739,757 shares of the stock traded hands, compared to its average volume of 3,476,920. The firm has a market cap of $141.35 billion, a price-to-earnings ratio of 38.35, a PEG ratio of 2.76 and a beta of 0.77. The firm has a 50 day moving average price of $194.11 and a 200 day moving average price of $209.06. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher's payout ratio is presently 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.